Where does Enanta Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Enanta Pharmaceuticals, Inc. ranks #2,539 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Enanta Pharmaceuticals, Inc. hold?

Enanta Pharmaceuticals, Inc. holds 153 US utility patents granted between 2015 and 2025, spanning 12 technology areas.

What is Enanta Pharmaceuticals, Inc.'s Innovation Score?

Enanta Pharmaceuticals, Inc. has an Innovation Score of 44.1 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Enanta Pharmaceuticals, Inc. focus on?

Enanta Pharmaceuticals, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 118 patents, ranking #59 of 3,165 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Enanta Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Enanta Pharmaceuticals, Inc.'s recent grant velocity is +43% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Enanta Pharmaceuticals, Inc.'s patents?

Enanta Pharmaceuticals, Inc.'s patents average 16.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Enanta Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Enanta Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 153 granted patents across 12 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Enanta ranks #2,539 of 49,997 tracked US assignees by granted-patent volume, with 153 patents across 12 technology areas.

#2,539
of 49,997 US assignees by volume: Top 27%
by Innovation Score (44.1/100): 16.0
avg claims per patent: +43%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2539 · US Corporation #2,539 · 153 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MID 153 grants
TOP-DECILE #2,539/49,997
PHOTO-FINISH Aurora Flight Sciences
CPC-FOCUS C07D · 12 areas
INNOV-PAR 44.1/100
CLAIMS-RICH 16.0 claims/avg
TYPE-USCORP US Corporation
VEL-UP +43% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aurora Flight Sciences Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Enanta’s 44.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 17.4 pts (40%) Velocity 4.8 pts (11%) Breadth 12.2 pts (28%) Claim depth 9.6 pts (22%)

Qualcomm Incorporated · highest

85
Ambiq Micro · near

44
CureVac · near

44
Enanta Pharmaceuticals · this assignee

44
Hutchison Medipharma · near

44
Qualys · near

44
3D Lighting… · lowest

7

What this shows Enanta's Innovation Score is 44.1/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Enanta?

Each dot is one of Enanta’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Enanta’s own 16.0 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Enanta vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Enanta's grants concentrate

Enanta Pharmaceuticals, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 77.1% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (24 grants) versus a trough of 3 in 2016. By volume, Enanta sits between Valeo Embrayages and Korea Institute Of Geoscience And Mineral Resources.

Enanta's three-year grant acceleration

From 2019–2021 to 2022–2024, Enanta Pharmaceuticals, Inc. moved from 64 to 46 grants (0.72x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,093. See the growth leaderboard.

Valeo Embrayages

154
Veniam

154
Aurora Flight Sci…

153
Ballogy

153
Flex

153
Gogoro

153
Kwangwoon Univers…

153
Korea Institute O…

153
Enanta Pharmaceut… ◀

153

What this shows Enanta holds 153 patents at rank #2,539, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Enanta

By rank, the assignees closest to #2,539 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Enanta's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Enanta, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Enanta ranks #59 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

CureVac AG 44 Ambiq Micro, Inc. 44 Qualys, Inc. 44 Hutchison Medipharma Limited 44

Similar claim depth

Nearest assignees by average claims per patent (16.0 here).

Monolithic Power Systems, Inc. 16.0 avg Hutchinson 16.0 avg Novaled GmbH 16.0 avg OVH 16.0 avg

Enanta's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Enanta Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	17	11.1%
2016	3	2.0%
2017	8	5.2%
2018	8	5.2%
2019	24	15.7%
2020	23	15.0%
2021	17	11.1%
2022	17	11.1%
2023	9	5.9%
2024	20	13.1%
2025partial year	7	4.6%

Which technologies does Enanta Pharmaceuticals, Inc. patent most?

C07D - Heterocyclic Compounds 118

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 93

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 81

C07J - Steroids 20

C07K - Peptides 16

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 10

Y02A - Technologies FOR Adaptation TO Climate Change 10

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 10

C07C - Acyclic OR Carbocyclic Compounds 9

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 5

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Enanta Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Enanta Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 77.1% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #2,539 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Enanta Pharmaceuticals, Inc. against Valeo Embrayages, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.